Beckman Coulter to acquire Siemens Healthcare Diagnostics' clinical microbiology business
Top Story
By: Katie Bell
Ref: NASDAQ, Siemens Healthcare, Beckman Coulter
Published: 07/16/2014
Danaher subsidiary Beckman Coulter entered into a definitive agreement to purchase Siemens Healthcare Diagnostics' clinical microbiology business, the companies announced on Wednesday. The transaction, of which financial terms were not disclosed, is expected to close in the first quarter of 2015.
Siemens' microbial identification and antibiotic sensitivity testing (ID/AST) business includes the MicroScan Instruments and MicroScan panels/consumables, along with data management solutions. Beckman Coulter Diagnostics president Arnd Kaldowski said that "adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care, adding that "the acquisition expands our product portfolio with differentiated analytical systems and menu...while driving continued growth."
Last year, Siemens Healthcare Diagnostics announced that it voluntarily recalled its MicroScan Synergies plus Negative and rapID/S plus Negative panels due to false results.
Siemens' microbial identification and antibiotic sensitivity testing (ID/AST) business includes the MicroScan Instruments and MicroScan panels/consumables, along with data management solutions. Beckman Coulter Diagnostics president Arnd Kaldowski said that "adding its ID/AST solutions to our existing products and services will create an opportunity to enhance our offerings to laboratory customers and improve patient care, adding that "the acquisition expands our product portfolio with differentiated analytical systems and menu...while driving continued growth."
Last year, Siemens Healthcare Diagnostics announced that it voluntarily recalled its MicroScan Synergies plus Negative and rapID/S plus Negative panels due to false results.